Incorporation of capMedical Inc and Other Updates

capAI (LSE: CPAI) is pleased to announce the incorporation of capMedical Inc, a wholly owned US subsidiary established to advance the Group's artificial intelligence ("AI")-driven medical and longevity initiatives in the United States.

The incorporation of capMedical Inc in the State of Delaware marks a new operational milestone as the Company initiates its capMedical division, which forms part of capAI's broader Identify, Incubate and Invent strategy.

This new structure mirrors the model established for capMedia Inc, the Group's US subsidiary supporting its media activities, and represents a further step in the structured build-out of the Company's transatlantic operating framework.

Together, these entities provide the foundation for collaboration, development, and future commercialisation of AI applications in media, medicine, and longevity.

capAI continues to assess opportunities consistent with its AI in medicine and longevity strategy. Any such initiatives will be pursued selectively and responsibly, with a focus on long-term value creation.

The Company intends to apply for an operational licence for capMedical Inc to conduct business in the State of California at the appropriate time. Once licensed, capMedical Inc will serve as the Group's principal US operating vehicle for medical, scientific, and longevity-focused initiatives, collaborations, and technology partnerships. Further US state registrations will be pursued as required.

Renaming of UK subsidiaries

The Company has also renamed its two UK subsidiaries: capMedia (UK) Ltd and capMedical (UK) Ltd. Any UK-based activities within these respective divisions will be undertaken through these vehicles.

Prospectus Submission

The Company also confirms that it has submitted a Prospectus to the Financial Conduct Authority and that the review process is well underway.

The Prospectus is designed to address current headroom restrictions and establish a framework that provides the Company with greater operational flexibility to support its strategic objectives. The Company shall make a further statement regarding the Prospectus as and when appropriate.

The Board remains committed to building long-term shareholder value through the disciplined execution of its AI-led operating strategy. capAI's approach continues to emphasise high efficiency, capital discipline, and responsible growth, with both Professor Ronjon Nag and Richard Edwards holding substantial shareholdings that align the interests of the Board with those of all shareholders.